• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Gemini Therapeutics Inc.

    1/23/24 5:47:19 PM ET
    $GMTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GMTX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001759241
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Disc Medicine, Inc.
    SEC File Number
    001-39438
    Address of Issuer
    321 ARSENAL STREET, SUITE 101
    WATERTOWN
    MASSACHUSETTS
    02472
    Phone
    (617) 674-9274
    Name of Person for Whose Account the Securities are To Be Sold
    Atlas Venture Opportunity Fund I, L.P.
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    10% Stockholder

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    BTIG, LLC
    600 Montgomery Street
    6th Floor
    San Francisco � CA � 94111
    825005625675.002414042801/23/2024
    Nasdaq


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common Stock10/07/2020Private PlacementIssuerCheckbox not checked8250010/07/2020Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Atlas Venture Opportunity Fund I, L.P.
    300 Technology Square
    8th Floor
    Cambridge � MA � 02139
    Common Stock12/12/2023519673263405.22
    Atlas Venture Opportunity Fund I, L.P.
    300 Technology Square
    8th Floor
    Cambridge � MA � 02139
    Common Stock12/13/20233548212875.15
    Atlas Venture Opportunity Fund I, L.P.
    300 Technology Square
    8th Floor
    Cambridge � MA � 02139
    Common Stock12/14/2023205491197518.68
    Atlas Venture Opportunity Fund I, L.P.
    300 Technology Square
    8th Floor
    Cambridge � MA � 02139
    Common Stock01/10/2024200001280000.00
    Atlas Venture Fund X, L.P.
    300 Technology Square
    8th Floor
    Cambridge � MA � 02139
    Common Stock12/12/2023779514895139.23
    Atlas Venture Fund X, L.P.
    300 Technology Square
    8th Floor
    Cambridge � MA � 02139
    Common Stock12/13/20235323319372.72
    Atlas Venture Fund X, L.P.
    300 Technology Square
    8th Floor
    Cambridge � MA � 02139
    Common Stock12/14/2023308251796365.93
    Atlas Venture Fund X, L.P.
    300 Technology Square
    8th Floor
    Cambridge � MA � 02139
    Common Stock01/10/2024300001920000.00

    144: Remarks and Signature

    Remarks
    Date of Notice
    01/23/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Atlas Venture Opportunity Fund I, L.P., By: /s/ Ommer Chohan

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $GMTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GMTX

    DatePrice TargetRatingAnalyst
    3/11/2022$5.00 → $2.00Buy → Neutral
    HC Wainwright & Co.
    3/3/2022$10.00 → $2.00Outperform → Market Perform
    SVB Leerink
    3/1/2022$23.00 → $1.50Buy → Hold
    Jefferies
    1/24/2022$15.00 → $10.00Outperform
    SVB Leerink
    12/20/2021$25.00 → $15.00Outperform
    SVB Leerink
    12/15/2021$20.00Buy
    HC Wainwright & Co.
    10/6/2021$20.00 → $18.00Buy
    Goldman Sachs
    More analyst ratings

    $GMTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Gemini Therapeutics Provides Corporate Update

      Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today provided a corporate update announcing a leadership transition, strategic evaluation and corporate restructuring. The Board of Directors has appointed Georges Gemayel, Ph.D., the Company's current Executive Chair, as interim President and Chief Executive Officer to succeed Jason Meyenburg, who has transitioned from his roles as President, CEO and Director and will continue to serve as an advisor to the Company. Additionally, the Company has initiated a process to evaluate strategic alternatives in order

      2/28/22 8:30:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of Board of Directors

      Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Georges Gemayel, Ph. D., as the Chair of the Company's Board of Directors. "I am pleased to welcome Georges to Gemini's Board of Directors during this important time in our Company's maturation, as we advance our lead program into the next stages of clinical development," said Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics. "Georges' broad management experience and proven track record of commercial and product development success wi

      5/3/21 7:00:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gemini Therapeutics Appoints Samuel Barone, M.D., as Chief Medical Officer

      Gemini Therapeutics, Inc. (NASDAQ:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Samuel Barone, M.D., as Gemini's Chief Medical Officer, effective immediately. "We are thrilled to welcome Sam to Gemini as Chief Medical Officer, where he will bring his expertise as a board-certified ophthalmologist specializing in the treatment of retinal and macular diseases," said Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics. "As we continue to advance our clinical pipeline, we will benefit tremendously from his two-plus deca

      4/12/21 8:00:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $GMTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Gemini Therapeutics downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded Gemini Therapeutics from Buy to Neutral and set a new price target of $2.00 from $5.00 previously

      3/11/22 6:36:28 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gemini Therapeutics downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Gemini Therapeutics from Outperform to Market Perform and set a new price target of $2.00 from $10.00 previously

      3/3/22 6:29:25 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gemini Therapeutics downgraded by Jefferies with a new price target

      Jefferies downgraded Gemini Therapeutics from Buy to Hold and set a new price target of $1.50 from $23.00 previously

      3/1/22 6:13:52 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic Protoporphyria

      WATERTOWN, Mass., Dec. 27, 2022 /PRNewswire/ -- Disc Medicine, Inc. ("Disc"), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that the U.S. Food and Drug Administration ("FDA") granted Orphan Drug Designation to bitopertin for the treatment of erythropoietic protoporphyria ("EPP"). Bitopertin is an investigational oral, selective inhibitor of glycine transporter 1 ("GlyT1") designed to modulate heme biosynthesis, and has been shown in preclinical studies to reduce accumulation of protoporphyrin IX ("PPIX"), the toxic metabolite that causes dise

      12/27/22 8:00:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Announces Several Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting

      WATERTOWN, Mass., Dec. 13, 2022 /PRNewswire/ -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients living with serious hematologic diseases, presented five posters spanning several of its hematology programs at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition held in New Orleans, LA. "Disc Medicine continues to make considerable progress towards the development of potentially first-in-class therapeutic candidates for hematologic disorders," said John

      12/13/22 9:00:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Disc Medicine Announces Multiple Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting

      CAMBRIDGE, Mass., Nov. 3, 2022 /PRNewswire/ -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that five abstracts related to several of its hematology programs have been accepted for poster presentation at the upcoming 64th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held in New Orleans, LA on December 10-13, 2022.  "We are pleased to have five abstracts selected for presentat

      11/3/22 9:00:00 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Gemini Therapeutics Inc. (Amendment)

      SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

      2/14/24 4:08:06 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Gemini Therapeutics Inc. (Amendment)

      SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

      2/13/24 6:51:49 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Gemini Therapeutics Inc. (Amendment)

      SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

      2/9/24 8:50:22 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Franchi Jean M. was granted 36,666 shares (SEC Form 4)

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      2/15/24 8:37:53 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Franchi Jean M.

      3 - Disc Medicine, Inc. (0001816736) (Issuer)

      2/15/24 8:33:28 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bitterman Kevin sold $6,934,125 worth of shares (102,500 units at $67.65) (SEC Form 4)

      4 - Disc Medicine, Inc. (0001816736) (Issuer)

      1/25/24 4:33:04 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMTX
    SEC Filings

    See more
    • Gemini Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Disc Medicine, Inc. (0001816736) (Filer)

      2/7/24 8:10:55 AM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Gemini Therapeutics Inc.

      144 - Disc Medicine, Inc. (0001816736) (Subject)

      1/23/24 5:47:19 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Gemini Therapeutics Inc.

      144 - Disc Medicine, Inc. (0001816736) (Subject)

      1/23/24 5:44:49 PM ET
      $GMTX
      Biotechnology: Pharmaceutical Preparations
      Health Care